News Nation Logo


Jubilant Life Sciences looking to acquire speciality pharma business in US

The Potential Acquisition Will Be Subject To Due Diligence, Satisfactory Agreements, Etc And Final Approval Of Jubilant Life Sciences.

PTI | Updated on: 21 Mar 2017, 02:01:14 PM
Representational Image of pharma industry (source: Getty)

New Delhi :

Jubilant Life Sciences on Tuesday said its subsidiary Jubilant Pharma will negotiate a potential acquisition of a speciality business in the US.

“The Board of Directors of Jubilant Pharma Ltd, a material wholly-owned subsidiary of the company in Singapore, has approved to negotiate a potential acquisition of a speciality pharma business in the United States using only internal accruals,” Jubilant Life Sciences said in a BSE filing.

The potential acquisition will be subject to due diligence, satisfactory agreements, etc and final approval of Jubilant Life Sciences.

It further said: “The proposed acquisition is a niche, profitable speciality pharma business with a strategic fit and is expected to provide a competitive edge for JPL’s existing business if it materialises”.

Shares of Jubilant Life Sciences were trading 0.59 per cent up at Rs 790 apiece on BSE. 

For all the Latest Business News, Companies & Commodities News, Download News Nation Android and iOS Mobile Apps.

First Published : 21 Mar 2017, 01:37:00 PM